Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 248

1.

Bivalent Llama Single-Domain Antibody Fragments against Tumor Necrosis Factor Have Picomolar Potencies due to Intramolecular Interactions.

Beirnaert E, Desmyter A, Spinelli S, Lauwereys M, Aarden L, Dreier T, Loris R, Silence K, Pollet C, Cambillau C, de Haard H.

Front Immunol. 2017 Jul 31;8:867. doi: 10.3389/fimmu.2017.00867. eCollection 2017.

2.

FSAP-mediated nucleosome release from late apoptotic cells is inhibited by autoantibodies present in SLE.

Marsman G, Stephan F, de Leeuw K, Bulder I, Ruinard JT, de Jong J, Westra J, Bultink IE, Voskuyl AE, Aarden LA, Luken BM, Kallenberg CG, Zeerleder S.

Eur J Immunol. 2016 Mar;46(3):762-71. doi: 10.1002/eji.201546010. Epub 2015 Dec 22.

3.

An improved monocyte activation test using cryopreserved pooled human mononuclear cells.

Solati S, Aarden L, Zeerleder S, Wouters D.

Innate Immun. 2015 Oct;21(7):677-84. doi: 10.1177/1753425915583365. Epub 2015 Apr 23.

PMID:
25907070
4.

Response to: 'The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region' by Rinaudo-Gaujous et al.

van Schie KA, Hart MH, de Groot ER, Kruithof S, Aarden LA, Wolbink GJ, Rispens T.

Ann Rheum Dis. 2015 Aug;74(8):e41. doi: 10.1136/annrheumdis-2015-207529. Epub 2015 Apr 8. No abstract available.

PMID:
25854585
5.

Interaction of Bordetella pertussis filamentous hemagglutinin with human TLR2: identification of the TLR2-binding domain.

Asgarian-Omran H, Amirzargar AA, Zeerleder S, Mahdavi M, van Mierlo G, Solati S, Jeddi-Tehrani M, Rabbani H, Aarden L, Shokri F.

APMIS. 2015 Feb;123(2):156-62. doi: 10.1111/apm.12332. Epub 2014 Oct 29.

PMID:
25353353
6.

The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region.

van Schie KA, Hart MH, de Groot ER, Kruithof S, Aarden LA, Wolbink GJ, Rispens T.

Ann Rheum Dis. 2015 Jan;74(1):311-4. doi: 10.1136/annrheumdis-2014-206237. Epub 2014 Oct 23.

PMID:
25342759
7.

Functional analysis of the anti-adalimumab response using patient-derived monoclonal antibodies.

van Schouwenburg PA, Kruithof S, Votsmeier C, van Schie K, Hart MH, de Jong RN, van Buren EE, van Ham M, Aarden L, Wolbink G, Wouters D, Rispens T.

J Biol Chem. 2014 Dec 12;289(50):34482-8. doi: 10.1074/jbc.M114.615500. Epub 2014 Oct 17. Review.

8.

Cooperation of factor VII-activating protease and serum DNase I in the release of nucleosomes from necrotic cells.

Stephan F, Marsman G, Bakker LM, Bulder I, Stavenuiter F, Aarden LA, Zeerleder S.

Arthritis Rheumatol. 2014 Mar;66(3):686-93. doi: 10.1002/art.38265.

9.

Key findings towards optimising adalimumab treatment: the concentration-effect curve.

Pouw MF, Krieckaert CL, Nurmohamed MT, van der Kleij D, Aarden L, Rispens T, Wolbink G.

Ann Rheum Dis. 2015 Mar;74(3):513-8. doi: 10.1136/annrheumdis-2013-204172. Epub 2013 Dec 10.

PMID:
24326008
10.

The minipig as an alternative non-rodent model for immunogenicity testing using the TNFα blockers adalimumab and infliximab.

van Mierlo GJ, Cnubben NH, Wouters D, Wolbink GJ, Hart MH, Rispens T, Ganderup NC, Kuper CF, Aarden L, Penninks AH.

J Immunotoxicol. 2014 Jan-Mar;11(1):62-71. doi: 10.3109/1547691X.2013.796023. Epub 2013 Jun 5.

PMID:
23738746
11.

A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies.

Garcês S, Antunes M, Benito-Garcia E, da Silva JC, Aarden L, Demengeot J.

Ann Rheum Dis. 2014 Jun;73(6):1138-43. doi: 10.1136/annrheumdis-2013-203296. Epub 2013 May 11.

PMID:
23666932
12.

Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation.

van Schouwenburg PA, Krieckaert CL, Rispens T, Aarden L, Wolbink GJ, Wouters D.

Ann Rheum Dis. 2013 Oct;72(10):1680-6. doi: 10.1136/annrheumdis-2012-202407. Epub 2013 Jan 7.

PMID:
23300118
13.

Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation.

van Schouwenburg PA, van de Stadt LA, de Jong RN, van Buren EE, Kruithof S, de Groot E, Hart M, van Ham SM, Rispens T, Aarden L, Wolbink GJ, Wouters D.

Ann Rheum Dis. 2013 Jan;72(1):104-9. doi: 10.1136/annrheumdis-2012-201445. Epub 2012 Jul 3.

PMID:
22759910
14.

IgG4 production against adalimumab during long term treatment of RA patients.

van Schouwenburg PA, Krieckaert CL, Nurmohamed M, Hart M, Rispens T, Aarden L, Wouters D, Wolbink GJ.

J Clin Immunol. 2012 Oct;32(5):1000-6. doi: 10.1007/s10875-012-9705-0. Epub 2012 May 24.

PMID:
22622790
15.

Tissue factor pathway inhibitor is an inhibitor of factor VII-activating protease.

Stephan F, Dienava-Verdoold I, Bulder I, Wouters D, Mast AE, Te Velthuis H, Aarden LA, Zeerleder S.

J Thromb Haemost. 2012 Jun;10(6):1165-71. doi: 10.1111/j.1538-7836.2012.04712.x.

16.

FSAP, a new player in inflammation?

Stephan F, Aarden LA, Zeerleder S.

Hamostaseologie. 2012;32(1):51-5. doi: 10.5482/ha-1187. Review.

PMID:
22252569
17.

Antibodies to constant domains of therapeutic monoclonal antibodies: anti-hinge antibodies in immunogenicity testing.

Rispens T, de Vrieze H, de Groot E, Wouters D, Stapel S, Wolbink GJ, Aarden LA.

J Immunol Methods. 2012 Jan 31;375(1-2):93-9. doi: 10.1016/j.jim.2011.09.011. Epub 2011 Oct 1.

PMID:
21986105
18.

Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients.

Jamnitski A, Krieckaert CL, Nurmohamed MT, Hart MH, Dijkmans BA, Aarden L, Voskuyl AE, Wolbink GJ.

Ann Rheum Dis. 2012 Jan;71(1):88-91. doi: 10.1136/annrheumdis-2011-200184. Epub 2011 Sep 12.

PMID:
21914626
19.

Differential effect of drug interference in immunogenicity assays.

Hart MH, de Vrieze H, Wouters D, Wolbink GJ, Killestein J, de Groot ER, Aarden LA, Rispens T.

J Immunol Methods. 2011 Sep 30;372(1-2):196-203. doi: 10.1016/j.jim.2011.07.019. Epub 2011 Jul 29.

PMID:
21824477
20.

Changes of ferritin and CRP levels in melanoma patients treated with adjuvant interferon-α (EORTC 18952) and prognostic value on treatment outcome.

Bouwhuis MG, Collette S, Suciu S, de Groot ER, Kruit WH, Ten Hagen TL, Aarden LA, Eggermont AM, Swaak AJ; EORTC Melanoma Group.

Melanoma Res. 2011 Aug;21(4):344-51. doi: 10.1097/CMR.0b013e328346c17f.

PMID:
21546857
21.

Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up.

Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, Dijkmans BA, Aarden L, Wolbink GJ.

JAMA. 2011 Apr 13;305(14):1460-8. doi: 10.1001/jama.2011.406.

PMID:
21486979
22.

Activation of factor VII-activating protease in human inflammation: a sensor for cell death.

Stephan F, Hazelzet JA, Bulder I, Boermeester MA, van Till JO, van der Poll T, Wuillemin WA, Aarden LA, Zeerleder S.

Crit Care. 2011;15(2):R110. doi: 10.1186/cc10131. Epub 2011 Apr 5.

23.

Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis.

Pascual-Salcedo D, Plasencia C, Ramiro S, Nuño L, Bonilla G, Nagore D, Ruiz Del Agua A, Martínez A, Aarden L, Martín-Mola E, Balsa A.

Rheumatology (Oxford). 2011 Aug;50(8):1445-52. doi: 10.1093/rheumatology/ker124. Epub 2011 Mar 22.

PMID:
21427177
24.

Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody.

Rispens T, Leeuwen Av, Vennegoor A, Killestein J, Aalberse RC, Wolbink GJ, Aarden LA.

Anal Biochem. 2011 Apr 15;411(2):271-6. doi: 10.1016/j.ab.2011.01.001. Epub 2011 Jan 7.

PMID:
21216215
25.

Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study.

Bartelds GM, de Groot E, Nurmohamed MT, Hart MH, van Eede PH, Wijbrandts CA, Crusius JB, Dijkmans BA, Tak PP, Aarden L, Wolbink GJ.

Arthritis Res Ther. 2010;12(6):R221. doi: 10.1186/ar3208. Epub 2010 Dec 27.

26.

Label-free assessment of high-affinity antibody-antigen binding constants. Comparison of bioassay, SPR, and PEIA-ellipsometry.

Rispens T, Te Velthuis H, Hemker P, Speijer H, Hermens W, Aarden L.

J Immunol Methods. 2011 Feb 28;365(1-2):50-7. doi: 10.1016/j.jim.2010.11.010. Epub 2010 Nov 27.

PMID:
21115013
27.

The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept.

Jamnitski A, Bartelds GM, Nurmohamed MT, van Schouwenburg PA, van Schaardenburg D, Stapel SO, Dijkmans BA, Aarden L, Wolbink GJ.

Ann Rheum Dis. 2011 Feb;70(2):284-8. doi: 10.1136/ard.2010.135111. Epub 2010 Nov 10.

PMID:
21068090
28.

Intravenous clusterin administration reduces myocardial infarct size in rats.

Van Dijk A, Vermond RA, Krijnen PA, Juffermans LJ, Hahn NE, Makker SP, Aarden LA, Hack E, Spreeuwenberg M, van Rossum BC, Meischl C, Paulus WJ, Van Milligen FJ, Niessen HW.

Eur J Clin Invest. 2010 Oct;40(10):893-902. doi: 10.1111/j.1365-2362.2010.02345.x.

PMID:
20854280
29.

A novel method for the detection of antibodies to adalimumab in the presence of drug reveals "hidden" immunogenicity in rheumatoid arthritis patients.

van Schouwenburg PA, Bartelds GM, Hart MH, Aarden L, Wolbink GJ, Wouters D.

J Immunol Methods. 2010 Oct 31;362(1-2):82-8. doi: 10.1016/j.jim.2010.09.005. Epub 2010 Sep 9.

PMID:
20833178
30.

Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies.

Tran L, Baars JW, Aarden L, Beijnen JH, Huitema AD.

Hum Antibodies. 2010;19(1):7-13. doi: 10.3233/HAB-2010-0215.

PMID:
20555126
31.

Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation.

de Vries MK, Brouwer E, van der Horst-Bruinsma IE, Spoorenberg A, van Denderen JC, Jamnitski A, Nurmohamed MT, Dijkmans BA, Aarden LA, Wolbink GJ.

Ann Rheum Dis. 2009 Nov;68(11):1787-8. doi: 10.1136/ard.2009.109702. No abstract available.

PMID:
19822712
32.

Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis.

Thurlings RM, Teng O, Vos K, Gerlag DM, Aarden L, Stapel SO, van Laar JM, Tak PP, Wolbink GJ.

Ann Rheum Dis. 2010 Feb;69(2):409-12. doi: 10.1136/ard.2009.109041. Epub 2009 Jul 12.

PMID:
19596693
33.

Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study.

Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ.

Ann Rheum Dis. 2010 May;69(5):817-21. doi: 10.1136/ard.2009.112847. Epub 2009 Jul 5.

PMID:
19581278
34.

Development and validation of an enzyme-linked immunosorbent assay for the quantification of trastuzumab in human serum and plasma.

Damen CW, de Groot ER, Heij M, Boss DS, Schellens JH, Rosing H, Beijnen JH, Aarden LA.

Anal Biochem. 2009 Aug 15;391(2):114-20. doi: 10.1016/j.ab.2009.05.030. Epub 2009 May 22.

PMID:
19464994
35.

Dealing with immunogenicity of biologicals: assessment and clinical relevance.

Wolbink GJ, Aarden LA, Dijkmans BA.

Curr Opin Rheumatol. 2009 May;21(3):211-5. Review.

PMID:
19399992
36.

High-throughput analysis of the C4 polymorphism by a combination of MLPA and isotype-specific ELISA's.

Wouters D, van Schouwenburg P, van der Horst A, de Boer M, Schooneman D, Kuijpers TW, Aarden LA, Hamann D.

Mol Immunol. 2009 Feb;46(4):592-600. doi: 10.1016/j.molimm.2008.07.028. Epub 2008 Dec 5.

PMID:
19062096
37.

Effects of smoking on the ex vivo cytokine production in periodontitis.

de Heens GL, Kikkert R, Aarden LA, van der Velden U, Loos BG.

J Periodontal Res. 2009 Feb;44(1):28-34. doi: 10.1111/j.1600-0765.2007.01047.x. Epub 2008 Oct 29.

PMID:
18973517
38.

Nucleosome-releasing factor: a new role for factor VII-activating protease (FSAP).

Zeerleder S, Zwart B, te Velthuis H, Stephan F, Manoe R, Rensink I, Aarden LA.

FASEB J. 2008 Dec;22(12):4077-84. doi: 10.1096/fj.08-110429. Epub 2008 Aug 27.

PMID:
18753248
39.

[The formation of infliximab and anti-infliximab immune complexes as an explanation for non-responding to infliximab treatment of rheumatoid arthritis: observational study in 4 patients].

van der Laken CJ, Voskuyl AE, Roos JC, Stigter van Walsum M, de Groot ER, Wolbink GJ, Dijkmans BA, Aarden LA.

Ned Tijdschr Geneeskd. 2008 Jul 26;152(30):1672-7. Dutch.

PMID:
18714521
40.

Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement.

Aarden L, Ruuls SR, Wolbink G.

Curr Opin Immunol. 2008 Aug;20(4):431-5. doi: 10.1016/j.coi.2008.06.011. Epub 2008 Jul 19. Review.

PMID:
18619538
41.

Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network.

Kuilman T, Michaloglou C, Vredeveld LC, Douma S, van Doorn R, Desmet CJ, Aarden LA, Mooi WJ, Peeper DS.

Cell. 2008 Jun 13;133(6):1019-31. doi: 10.1016/j.cell.2008.03.039.

42.

Cytokine induction by pyrogens: comparison of whole blood, mononuclear cells, and TLR-transfectants.

Kikkert R, de Groot ER, Aarden LA.

J Immunol Methods. 2008 Jul 20;336(1):45-55. doi: 10.1016/j.jim.2008.03.010. Epub 2008 Apr 22.

PMID:
18456276
43.

Preferential decrease in IgG4 anti-citrullinated protein antibodies during treatment with tumour necrosis factor blocking agents in patients with rheumatoid arthritis.

Bos WH, Bartelds GM, Vis M, van der Horst AR, Wolbink GJ, van de Stadt RJ, van Schaardenburg D, Dijkmans BA, Lems WF, Nurmohamed MT, Aarden L, Hamann D.

Ann Rheum Dis. 2009 Apr;68(4):558-63. doi: 10.1136/ard.2008.088401. Epub 2008 Apr 29.

PMID:
18445623
44.

Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis.

de Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT, Aarden LA, Stapel SO, Peters MJ, van Denderen JC, Dijkmans BA, Wolbink GJ.

Ann Rheum Dis. 2009 Apr;68(4):531-5. doi: 10.1136/ard.2008.089979. Epub 2008 Mar 28.

PMID:
18375542
45.

A plasma nucleosome releasing factor (NRF) with serine protease activity is instrumental in removal of nucleosomes from secondary necrotic cells.

Zeerleder S, Zwart B, te Velthuis H, Manoe R, Bulder I, Rensink I, Aarden LA.

FEBS Lett. 2007 Nov 27;581(28):5382-8. Epub 2007 Oct 30.

46.

Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange.

van der Neut Kolfschoten M, Schuurman J, Losen M, Bleeker WK, Martínez-Martínez P, Vermeulen E, den Bleker TH, Wiegman L, Vink T, Aarden LA, De Baets MH, van de Winkel JG, Aalberse RC, Parren PW.

Science. 2007 Sep 14;317(5844):1554-7.

47.

Potentiation of Toll-like receptor-induced cytokine production by (1-->3)-beta-D-glucans: implications for the monocyte activation test.

Kikkert R, Bulder I, de Groot ER, Aarden LA, Finkelman MA.

J Endotoxin Res. 2007;13(3):140-9.

PMID:
17621556
48.

Activation of toll-like receptors 2 and 4 by gram-negative periodontal bacteria.

Kikkert R, Laine ML, Aarden LA, van Winkelhoff AJ.

Oral Microbiol Immunol. 2007 Jun;22(3):145-51.

PMID:
17488439
49.

Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation.

de Vries MK, Wolbink GJ, Stapel SO, de Vrieze H, van Denderen JC, Dijkmans BA, Aarden LA, van der Horst-Bruinsma IE.

Ann Rheum Dis. 2007 Sep;66(9):1252-4. Epub 2007 May 1.

50.

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis.

Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ.

Ann Rheum Dis. 2007 Jul;66(7):921-6. Epub 2007 Feb 14.

Supplemental Content

Loading ...
Support Center